Small molecules that can modulate protein interactions found in disease states

Nereid Therapeutics focuses on leveraging the science of biomolecular condensates, particularly through the study of intracellular liquid-liquid phase separation (LLPS). Founded on the pioneering work of Dr. Clifford Brangwynne, the company has developed innovative technologies that allow for the systematic measurement of LLPS within mammalian cells. This capability is crucial as it enables researchers to observe and quantify the formation and behavior of membrane-less compartments, which play significant roles in gene regulation and various disease processes. By integrating advanced microscopy and computer vision techniques, Nereid aims to discover small molecules that can modulate protein interactions associated with diseases, thereby opening new avenues for therapeutic development.

The company employs a unique approach that combines principles of soft matter physics with cell biology to address challenging diseases such as cancers, neurodegenerative disorders, and inflammatory conditions. Nereid's platform enhances the understanding of the biomolecular forces driving phase separation and utilizes machine learning to amplify insights gained from these studies. This innovative methodology not only accelerates the translation of findings into potential therapeutics but also charts a new path in drug discovery by modifying the phase behavior of living cells, ultimately aiming to create effective treatments for unmet medical needs.

United States

Nereid starts with approaches to see and measure the biomolecular forces driving phase separation, amplifying insights with machine learning, and accelerating translation with cell biology and medicinal chemistry. Nereid’s platform uses physics to discover therapeutics that can modify the phase behavior of livingcells.

Nereid Therapeutics

Company Details